Gladstone Institutional Advisory’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.33M | Sell |
33,122
-26
| -0.1% | -$5.59K | 0.26% | 76 |
|
|
2026
Q1 | $7.21M | Buy |
33,148
+2,209
| +7% | +$490K | 0.27% | 79 |
|
|
2025
Q4 | $7.07M | Sell |
30,939
-87
| -0.3% | -$19.8K | 0.27% | 86 |
|
|
2025
Q3 | $7.18M | Buy |
31,026
+173
| +0.6% | +$35.2K | 0.28% | 83 |
|
|
2025
Q2 | $5.73M | Buy |
30,853
+1,314
| +4% | +$244K | 0.24% | 101 |
|
|
2025
Q1 | $6.19M | Buy |
29,539
+1,810
| +7% | +$352K | 0.29% | 85 |
|
|
2024
Q4 | $4.93M | Buy |
27,729
+6
| +0% | +$1.1K | 0.23% | 101 |
|
|
2024
Q3 | $5.47M | Sell |
27,723
-328
| -1% | -$61.2K | 0.27% | 94 |
|
|
2024
Q2 | $4.81M | Buy |
28,051
+2,261
| +9% | +$375K | 0.25% | 107 |
|
|
2024
Q1 | $4.7M | Buy |
25,790
+3,427
| +15% | +$591K | 0.26% | 106 |
|
|
2023
Q4 | $3.47M | Buy |
22,363
+1,325
| +6% | +$193K | 0.19% | 135 |
|
|
2023
Q3 | $3.14M | Buy |
21,038
+1,551
| +8% | +$228K | 0.2% | 128 |
|
|
2023
Q2 | $2.63M | Sell |
19,487
-3,239
| -14% | -$475K | 0.16% | 163 |
|
|
2023
Q1 | $3.62M | Sell |
22,726
-1,230
| -5% | -$188K | 0.23% | 127 |
|
|
2022
Q4 | $3.87M | Sell |
23,956
-4,169
| -15% | -$639K | 0.27% | 106 |
|
|
2022
Q3 | $3.77M | Sell |
28,125
-9,588
| -25% | -$1.38M | 0.3% | 86 |
|
|
2022
Q2 | $5.78M | Sell |
37,713
-8,753
| -19% | -$1.34M | 0.46% | 45 |
|
|
2022
Q1 | $7.53M | Buy |
46,466
+24,792
| +114% | +$3.6M | 0.51% | 40 |
|
|
2021
Q4 | $2.94M | Buy |
21,674
+6,190
| +40% | +$731K | 0.23% | 120 |
|
|
2021
Q3 | $1.67M | Sell |
15,484
-813
| -5% | -$92.9K | 0.16% | 165 |
|
|
2021
Q2 | $1.84M | Buy |
16,297
+4,603
| +39% | +$518K | 0.22% | 116 |
|
|
2021
Q1 | $1.26M | Buy |
11,694
+3,805
| +48% | +$407K | 0.2% | 114 |
|
|
2020
Q4 | $845K | Sell |
7,889
-672
| -8% | -$64.6K | 0.17% | 119 |
|
|
2020
Q3 | $750K | Sell |
8,561
-8,596
| -50% | -$809K | 0.18% | 114 |
|
|
2020
Q2 | $1.68M | Buy |
17,157
+5,374
| +46% | +$473K | 0.43% | 57 |
|
|
2020
Q1 | $898K | Buy |
11,783
+3,106
| +36% | +$265K | 0.23% | 91 |
|
|
2019
Q4 | $768K | Sell |
8,677
-3,166
| -27% | -$263K | 0.19% | 103 |
|
|
2019
Q3 | $897K | Sell |
11,843
-187
| -2% | -$12.8K | 0.23% | 92 |
|
|
2019
Q2 | $875K | Buy |
12,030
+8,469
| +238% | +$666K | 0.27% | 83 |
|
|
2019
Q1 | $287K | Sell |
3,561
-107
| -3% | -$8.75K | 0.11% | 157 |
|
|
2018
Q4 | $338K | Buy |
+3,668
| New | +$323K | 0.2% | 117 |
|
Other funds holding ABBV
Gladstone Institutional Advisory's ABBV Position: Q2 2026 in Review
Gladstone Institutional Advisory reduced its AbbVie (ABBV) stake by 0.08% in Q2 2026, selling an estimated $5.59K and leaving 33,122 shares worth $8.33M. The position accounts for 0.26% of the portfolio, ranked #76.
Gladstone Institutional Advisory first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Gladstone Institutional Advisory held 33,122 shares of AbbVie worth $8.33M as of Q2 2026.
- Gladstone Institutional Advisory sold 26 AbbVie shares in Q2 2026, an estimated $5.59K.
- AbbVie made up 0.26% of Gladstone Institutional Advisory's portfolio in Q2 2026, its #76 holding.
- Gladstone Institutional Advisory first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Gladstone Institutional Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.